Shelly Lu, MD, has been working in the fields of S-adenosylmethionine and glutathione metabolism for 30 years and has received uninterrupted funding from the National Institutes of Health (NIH) since 1992. Lu currently has active NIH-funded research programs that investigate molecular mechanisms of fatty liver, liver injury, liver cancer (both primary and metastatic). Many of the research projects have translational applications, such as identifying biomarkers that can differentiate simple fatty liver from those with more a severe form called nonalcoholic steatohepatitis, and examining agents that are effective in the prevention and treatment of liver and colon cancer. Lu is also the PI of a NIH-funded clinical trial examining the efficacy of S-adenosylmethionine in patients with alcoholic cirrhosis.